Achieve Life Sciences Advances U.S. Manufacturing Shift for Cytisinicline Ahead of NDA Resubmission

A Complete Response Letter expected by June 20, 2026 is reshaping Achieve Life Sciences' path to market for cytisinicline, forcing a manufacturing pivot that now defines the company's regulatory timeline. The CRL follows an Official Action Indicated classification issued to the company's prior contract manufacturer for general GMP deficiencies, observations the company states were not specific to cytisinicline.

To address the gap, Achieve has partnered with U.S.-based Adare Pharma Solutions as its new primary commercial manufacturer. The company reports completing an analytical method technology transfer to the Adare site, manufacturing its first cytisinicline engineering batch, and fully qualifying all testing procedures at the facility, standard process validation checkpoints under 21 CFR Part 211 before a site can be named in a regulatory submission.

For QA directors and regulatory leads tracking the resubmission, the practical consequence is a compressed fourth-quarter 2026 NDA resubmission window. Naming Adare as the primary manufacturer in that filing will require the submission package to reflect the completed technology transfer, batch data from the engineering run, and validated analytical methods, documentation that the company indicates is now in place.

The manufacturing transition runs alongside a $354 million private placement, structured as $180 million upfront and up to $174 million in milestone-driven warrants exercisable around FDA approval. Proceeds are earmarked for the ORCA-V2 Phase 3 trial targeting e-cigarette cessation, commercialization activities, and working capital. Incoming CEO Andrew D. Goldberg, MD, who also joins the board, framed the quarter as foundational work ahead of a commercial launch.

Leadership changes add further operational variables. Chief Commercial Officer Jaime Xinos departs effective May 31, 2026, after nearly nine years with the company. Three new board members bring commercialization and governance experience; Dr. Lucian Iancovici assumes the chairmanship. The company indicated a separate announcement would detail reorganized commercial leadership.

The Q4 2026 NDA resubmission, with Adare named as primary manufacturer, will serve as the first measurable test of whether the technology transfer and process validation work completed this quarter meets FDA's CMC expectations for a pre-commercial sterile-adjacent oral solid dosage program.

Source: Achieve Life Sciences, Inc. via GlobeNewswire, May 12, 2026. Conference call scheduled 8:30 AM EDT, May 12, 2026.